Search

Recursion Pharmaceuticals Inc

Închisă

SectorSănătate

3.41 6.9

Rezumat

Modificarea prețului

24h

Curent

Minim

3.18

Maxim

3.45

Indicatori cheie

By Trading Economics

Venit

-14M

-131M

Vânzări

1.2M

7.7M

EPS

-0.25

Marjă de profit

-1,708.018

Angajați

600

EBITDA

-10M

-113M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+101.04% upside

Dividende

By Acuity

Următoarele câștiguri

4 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

259M

1.9B

Deschiderea anterioară

-3.49

Închiderea anterioară

3.41

Sentimentul știrilor

By Acuity

100%

0%

322 / 339 Clasament în Healthcare

Recursion Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 sept. 2026, 19:46 UTC

Recursion Pharmaceuticals Inc shares are higher during Friday's session, despite a slight pullback from earlier highs. No specific news was identified for the move.

10 sept. 2026, 23:16 UTC

No specific news was identified for Recursion Pharmaceuticals Inc. during after-market hours. The stock remained roughly flat since Thursday's close.

9 sept. 2026, 23:06 UTC

Recursion Pharmaceuticals Inc shares are higher in after-market trading, following a notable peak earlier in the session with no specific news identified.

8 sept. 2026, 22:51 UTC

Recursion Pharmaceuticals Inc shares are higher in after-market trading. The stock remains above its 20-day moving average and near the upper end of its one-month range.

4 sept. 2026, 20:08 UTC

Recursion Pharmaceuticals shares are higher today, continuing an upward trend since Thursday's close, amid broader market dynamics following a strong jobs report.

3 sept. 2026, 23:21 UTC

Correlated Moves

Recursion Pharmaceuticals Inc. shares declined in after-market trading, following a peak shortly after the market closed and amid broader market weakness.

2 sept. 2026, 23:06 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market trading. The decline comes amid a weaker ADP private payrolls report impacting overall market sentiment.

1 sept. 2026, 20:09 UTC

Recursion Pharmaceuticals Inc. shares are lower, following broader market declines amid rising oil prices and increasing U.S. Treasury yields. No specific company news was identified.

31 aug. 2026, 23:06 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours. Market sentiment reflects recent comments from Federal Reserve Chair Kevin Warsh on inflation and interest rates.

28 aug. 2026, 23:51 UTC

Recursion Pharmaceuticals Inc shares are higher in after-market hours, following three consecutive lower finishes. No specific news was identified to explain the movement.

27 aug. 2026, 23:02 UTC

Recursion Pharmaceuticals Inc shares are trading higher in after-market hours. No specific news was identified to explain the price movement.

26 aug. 2026, 20:08 UTC

Correlated Moves

Recursion Pharmaceuticals is declining amid a broader downturn in the Biotechnology sub-sector, with the ARK Genomic Revolution ETF also experiencing losses.

25 aug. 2026, 23:01 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

24 aug. 2026, 20:02 UTC

News
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower amid broader market declines, with analysts rating the stock as a "Hold" and price targets between $5.30 and $10.00.

21 aug. 2026, 20:06 UTC

Recursion Pharmaceuticals Inc shares are higher during Friday's session, reflecting strong momentum since Thursday's close amid favorable conditions in the biotechnology sector.

20 aug. 2026, 20:06 UTC

Social Media
Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today, reflecting broader market trends. The stock's decline aligns with weakness in correlated assets.

19 aug. 2026, 23:01 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours after a volatile session, declining from the upper end of its one-month range.

18 aug. 2026, 20:04 UTC

Correlated Moves

Recursion Pharmaceuticals Inc shares are lower today amid broader market pressures on small-cap stocks and rising U.S. Treasury yields affecting sentiment.

17 aug. 2026, 19:36 UTC

Correlated Moves
News

Recursion Pharmaceuticals shares decline as Morgan Stanley cuts the price target to $5.30 from $5.50, reflecting ongoing valuation concerns.

12 aug. 2026, 19:56 UTC

Recursion Pharmaceuticals Inc is trading lower, reflecting a decline from Tuesday's close. The stock remains above its 20-day moving average despite today's pullback.

11 aug. 2026, 19:36 UTC

News

Recursion Pharmaceuticals Inc. is higher today amid positive market sentiment and over $500 million in milestone payments from partnerships with Genentech/Roche and Sanofi.

10 aug. 2026, 20:06 UTC

Social Media

Recursion Pharmaceuticals Inc is higher Monday amid ongoing interest, despite social media concerns about its clinical pipeline and integration challenges with Exscientia.

7 aug. 2026, 23:26 UTC

Recursion Pharmaceuticals Inc. shares have been roughly flat in after-market trading, with minimal fluctuations since Friday's close. The stock remains above its 20-day moving average.

6 aug. 2026, 23:26 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Thursday's close amid a strengthening U.S. Dollar.

5 aug. 2026, 23:41 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours, amid declining sentiment in US markets despite positive momentum in Asian indices.

4 aug. 2026, 23:31 UTC

Recursion Pharmaceuticals Inc shares are lower in after-market hours following a volatile session with no specific news to explain the movement.

3 aug. 2026, 20:03 UTC

Correlated Moves
News

Recursion Pharmaceuticals Inc shares are higher amid strong market sentiment, supported by a rise in the Russell 2000 Index and notable intraday volatility.

31 iul. 2026, 23:32 UTC

News

Recursion Pharmaceuticals Inc shares are lower in after-market hours, reflecting broader market trends amid mixed performance among major tech stocks and upcoming economic data.

30 iul. 2026, 23:26 UTC

Recursion Pharmaceuticals Inc. shares were roughly flat in after-market hours, trading within a narrow range since Thursday's close, significantly below its 20-day moving average.

29 iul. 2026, 22:51 UTC

Recursion Pharmaceuticals Inc is higher in after-market trading, reflecting broader market gains amid the Federal Reserve's decision to maintain interest rates.

Comparație

Modificare preț

Recursion Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

101.04% sus

Prognoză pe 12 luni

Medie 6.433 USD  101.04%

Maxim 8 USD

Minim 5.3 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRecursion Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

4 ratings

1

Cumpărare

3

Păstrare

0

Vânzare

Sentiment

By Acuity

322 / 339 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat